| Park View Post Acute | |
| 3751 Montgomery Dr, Santa Rosa, California 95405 | |
| (707) 525-1250 | |
| Name | Park View Post Acute |
|---|---|
| Location | 3751 Montgomery Dr, Santa Rosa, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 116 |
| Occupancy Rate | 87.76% |
| Medicare ID (CCN) | 056411 |
| Legal Business Name | Ensign Montgomery Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1104825520 |
| Organization Name | ENSIGN MONTGOMERY LLC |
| Doing Business As | PARK VIEW POST ACUTE |
| Address | 3751 Montgomery Dr, Santa Rosa, CA 95405 |
| Phone Number | 707-525-1250 |
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
The popularity of stomach surgery in the United States to resolve obesity has greatly increased in the last few years but operating on obese children has rarely been done because of the considerable risks involved.
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances, a Journal of the American Society of Hematology.
Researchers from the US recently assessed if severe COVID-19 is linked to procoagulant dysfunction of the endothelium and changes in the Tie2-angiopoietin axis. They assessed circulating endothelial markers in a study cohort of 98 patients with mild, moderate, or severe COVID-19. This study is published on the medRxiv* preprint server.
Starpharma Holdings Limited (ASX:SPL,OTCQX:SPHRY) today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
The popularity of stomach surgery in the United States to resolve obesity has greatly increased in the last few years but operating on obese children has rarely been done because of the considerable risks involved.
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances, a Journal of the American Society of Hematology.
Researchers from the US recently assessed if severe COVID-19 is linked to procoagulant dysfunction of the endothelium and changes in the Tie2-angiopoietin axis. They assessed circulating endothelial markers in a study cohort of 98 patients with mild, moderate, or severe COVID-19. This study is published on the medRxiv* preprint server.
Starpharma Holdings Limited (ASX:SPL,OTCQX:SPHRY) today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 3.66 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.77 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 30.43 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.42 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 7.09 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.72 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.19 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.53 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 24.5 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 12.14 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 3.4 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.97 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 69.6 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 100 | 82.93 |
News Archive
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus.
The popularity of stomach surgery in the United States to resolve obesity has greatly increased in the last few years but operating on obese children has rarely been done because of the considerable risks involved.
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances, a Journal of the American Society of Hematology.
Researchers from the US recently assessed if severe COVID-19 is linked to procoagulant dysfunction of the endothelium and changes in the Tie2-angiopoietin axis. They assessed circulating endothelial markers in a study cohort of 98 patients with mild, moderate, or severe COVID-19. This study is published on the medRxiv* preprint server.
Starpharma Holdings Limited (ASX:SPL,OTCQX:SPHRY) today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.
› Verified 4 days ago
Creekside Rehabilitation & Behavioral Health Location: 850 Sonoma Ave, Santa Rosa, California 95404 Phone: (707) 544-7750 | |
Northvine Postacute Care Location: 446 Arrowood Dr, Santa Rosa, California 95407 Phone: (707) 528-2100 | |
Summerfield Health Care Center Location: 1280 Summerfield Rd, Santa Rosa, California 95405 Phone: (707) 539-1515 | |